1
|
Liu X, Park J, Xia S, Liang B, Yang S, Wang Y, Syrkina O, Lavis N, Liu S, Zhao C, Ding J, Hu J, Samson SI, de Bruijn IA, Li X, Liu Q, Luo H, Lv Q, Su M, Xie Z, Xia H, You W, Zhang W, Zheng Y, Zhu G, Zhang Z, Zhang H, Abalos K, Beyer YJ, Zhang M, Moreau C, Deng C, Salamand C, Tabar C, Ao R, Mallett Moore T, Jouve A, Frago C, A R, Jean Baria E, Camille S, Cao X, Cathcart D, Chabanon AL, Chen N, Feng H, Fontvieille AI, Hagenbach A, He H, Inamdar A, Janosczyk H, Lau A, Petit C, Philippe W, See S, Serradell-Vallejo L, Tourault A, Wu S, Yan M, Yue C, Zhang X, Zhang H, Zhu Y, Li J, Mao H, Yang H, Yang Y, Yi X, Du Z, Guo L, Wang K. Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies. Hum Vaccin Immunother 2022; 18:2132798. [PMID: 36328438 DOI: 10.1080/21645515.2022.2132798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
WHO UNIVERSAL TRIAL NUMBERS (UTNS) U1111-1174-4615 and U1111-1174-4698. CLINICALTRIALS.GOV NCT04210349 and NCT03430089.
Collapse
Affiliation(s)
- Xiaoqiang Liu
- Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, China
| | - Juliana Park
- Global Clinical Development, Sanofi, Sydney, Australia
| | - Shengli Xia
- Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, China
| | - Bin Liang
- China Medical, Sanofi, Beijing, China
| | - Shuangmin Yang
- Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, China
| | - Yanxia Wang
- Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, China
| | - Olga Syrkina
- Global Pharmacovigilance, Sanofi, Swiftwater, Pennsylvania, USA
| | | | - Shuzhen Liu
- Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Chenyan Zhao
- Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Jian Ding
- China Medical, Sanofi, Beijing, China
| | - Jieqiong Hu
- Global Clinical Development, Sanofi, Sydney, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Yang X, Zhao H, Li Z, Zhu A, Ren M, Geng M, Li Y, Qin Y, Feng L, Peng Z, An Z, Zheng J, Li Z, Feng Z. Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2021; 9:vaccines9020079. [PMID: 33498688 PMCID: PMC7912587 DOI: 10.3390/vaccines9020079] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/20/2021] [Accepted: 01/20/2021] [Indexed: 12/03/2022] Open
Abstract
Influenza endangers human health but can be prevented in part by vaccination. Assessing influenza vaccine effectiveness (VE) provides scientific evidence for developing influenza vaccination policy. We conducted a systematic review and meta-analysis of studies that evaluated influenza VE in mainland China. We searched six relevant databases as of 30 August 2019 to identify studies and used Review Manager 5.3 software to analyze the included studies. The Newcastle–Ottawa scale was used to assess the risk of publication bias. We identified 1408 publications, and after removing duplicates and screening full texts, we included 21 studies in the analyses. Studies were conducted in Beijing, Guangzhou, Suzhou, and Zhejiang province from the 2010/11 influenza season through the 2017/18 influenza season. Overall influenza VE for laboratory confirmed influenza was 36% (95% CI: 25–46%). In the subgroup analysis, VE was 45% (95% CI: 18–64%) for children 6–35 months who received one dose of influenza vaccine, and 57% (95% CI: 50–64%) who received two doses. VE was 47% (95% CI: 39–54%) for children 6 months to 8 years, and 18% (95% CI: 0–33%) for adults ≥60 years. For inpatients, VE was 21% (95% CI: −11–44%). We conclude that influenza vaccines that were used in mainland China had a moderate effectiveness, with VE being higher among children than the elderly. Influenza VE should be continuously monitored in mainland China to provide evidence for policy making and improving uptake of the influenza vaccine.
Collapse
Affiliation(s)
- Xiaokun Yang
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Hongting Zhao
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Zhili Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Aiqin Zhu
- Division of Infectious Disease Prevention and Disinfection Management, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China;
| | - Minrui Ren
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Mengjie Geng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Yu Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Ying Qin
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Luzhao Feng
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;
| | - Zhibin Peng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 102206, China;
| | - Jiandong Zheng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| | - Zhongjie Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing 102206, China
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| |
Collapse
|
3
|
Zhang W, Gao J, Chen L, Tian J, Biggerstaff M, Zhou S, Situ S, Wang Y, Zhang J, Millman AJ, Greene CM, Zhang T, Zhao G. Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons. Vaccine 2020; 38:8200-8205. [PMID: 33176936 PMCID: PMC7728434 DOI: 10.1016/j.vaccine.2020.10.069] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Revised: 10/17/2020] [Accepted: 10/21/2020] [Indexed: 01/14/2023]
Abstract
BACKGROUND There are few estimates of vaccination-averted influenza-associated illnesses in China. METHODS We used a mathematical model and Monte Carlo algorithm to estimate numbers and 95% confidence intervals (CI) of influenza-associated outcomes (hospitalization, illness, and medically-attended (MA) illness) averted by vaccination among children aged 6-59 months in Suzhou from October 2011-September 2016. Influenza illnesses included non-hospitalized MA influenza illnesses and non-MA influenza illnesses. The numbers of influenza-associated outcomes averted by vaccination were the difference between the expected burden if there were no vaccination given and the observed burden with vaccination. The model incorporated the disease burden estimated based on surveillance data from Suzhou University Affiliated Children's Hospital (SCH) and data from health utilization surveys conducted in the catchment area of SCH, age-specific estimates of influenza vaccination coverage in Suzhou from the Expanded Program on Immunization database, and influenza vaccine effectiveness estimates from previous publications. Averted influenza estimations were presented as absolute numbers and in terms of the prevented fraction (PF). A hypothetical scenario with 50% coverage (but identical vaccine effectiveness) over the study period was also modeled. RESULTS In ~250,000 children, influenza vaccination prevented an estimated 731 (CI: 549-960) influenza hospitalizations (PF: 6.2% of expected, CI: 5.8-6.6%) and 10,024 (7593-12,937) influenza illnesses (PF: 6.5%, 6.4-6.7%), of which 8342 (6338-10,768) were MA (PF: 6.6%, 6.4-6.7%) from 2011 to 2016. The PFs declined each year along with decreasing influenza vaccination coverage. If 50% of the study population had been vaccinated over time, the estimated numbers of averted cases during the study period would have been 4059 (3120-5762) influenza hospitalizations (PF: 27.2%, 26.4-27.9%) and 56,215 (42,925-78,849) influenza illnesses (PF: 28.5%, 28.3-28.7%), of which 46,596 (35,662-65,234) would be MA (PF: 28.5%, 28.3-28.7%). CONCLUSION Influenza vaccination is estimated to have averted influenza-associated illness outcomes even with low coverage in children aged 6-59 months in Suzhou. Increasing influenza vaccination coverage in this population could further reduce illnesses and hospitalizations.
Collapse
Affiliation(s)
- Wanqing Zhang
- Department of Epidemiology, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
| | - Junmei Gao
- Department of Epidemiology, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
| | - Liling Chen
- Suzhou Center for Disease Control and Prevention, Suzhou, China
| | - Jianmei Tian
- Suzhou University Affiliated Children's Hospital, Suzhou, China
| | - Matthew Biggerstaff
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Suizan Zhou
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Sujian Situ
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Yin Wang
- Department of Epidemiology, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
| | - Jun Zhang
- Suzhou Center for Disease Control and Prevention, Suzhou, China
| | - Alexander J Millman
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Carolyn M Greene
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Tao Zhang
- Department of Epidemiology, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
| | - Genming Zhao
- Department of Epidemiology, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
| |
Collapse
|
4
|
Li X, Lu H, Wu H, Chen Q, Wu P, Pan Q. Factors impacting self-pay pediatric vaccine utilization in China: a large-scale maternal survey. J Int Med Res 2020; 48:300060520948752. [PMID: 32847451 PMCID: PMC7457670 DOI: 10.1177/0300060520948752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVES Utilization of self-pay vaccines worldwide is very low, especially in China; the reasons for this are unclear. We aimed to identify factors that impact the decision among Chinese mothers to utilize self-pay vaccines for their children. METHODS Mothers who were hospitalized at two hospitals in Zhanjiang City and who agreed to participate by completing the required questionnaire were eligible for this study. RESULTS In total, 7518 respondents (n = 7592) completed the questionnaire and were included in this survey. The self-pay option was largely elected by mothers with one child, compared with those who had two or more children. Similarly, utilization by workers at government agencies and organizations was higher than that among factory workers or unemployed respondents. Mothers with a college degree or above had higher utilization than those with a high school level education or lower. The main issues affecting maternal decisions to utilize self-pay pediatric vaccines were safety, the protective effect, and the high cost. CONCLUSION Mothers with higher socioeconomic status were more inclined to self-pay for pediatric vaccines. Steps taken to enhance public awareness about the safety and protective benefits of self-pay vaccines, as well as lowering their cost will likely encourage broader utilization of these vaccines.
Collapse
Affiliation(s)
- Xinxin Li
- Clinical Research Center, Institute of Nephrology, Division of Rheumatology, Affiliated Hospital of Guangdong Medical University, Guangdong, China
| | - Haiyan Lu
- Department of Vaccination, Xiashan Maternal and Child Healthy Hospital, Guangdong, China
| | - Han Wu
- Clinical Research Center, Institute of Nephrology, Division of Rheumatology, Affiliated Hospital of Guangdong Medical University, Guangdong, China
| | - Qiuhua Chen
- Clinical Research Center, Institute of Nephrology, Division of Rheumatology, Affiliated Hospital of Guangdong Medical University, Guangdong, China
| | - Ping Wu
- Clinical Research Center, Institute of Nephrology, Division of Rheumatology, Affiliated Hospital of Guangdong Medical University, Guangdong, China
| | - Qingjun Pan
- Clinical Research Center, Institute of Nephrology, Division of Rheumatology, Affiliated Hospital of Guangdong Medical University, Guangdong, China
| |
Collapse
|